These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35100303)

  • 1. HRSV prefusion-F protein with Adju-Phos adjuvant induces long-lasting Th2-biased immunity in mice.
    Li H; Ren H; Zhou Y; Zhang Y; Cao L; Xu W
    PLoS One; 2022; 17(1):e0262231. PubMed ID: 35100303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human respiratory syncytial virus F protein expressed in Pichia pastoris or Escherichia coli induces protective immunity without inducing enhanced respiratory disease in mice.
    Li H; Cao L; Zhang Y; Ren H; Zhao P; Xu W
    Arch Virol; 2020 May; 165(5):1057-1067. PubMed ID: 32144542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection.
    Eichinger KM; Kosanovich JL; Gidwani SV; Zomback A; Lipp MA; Perkins TN; Oury TD; Petrovsky N; Marshall CP; Yondola MA; Empey KM
    Front Immunol; 2020; 11():1673. PubMed ID: 32849580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RBF Protein with MA103 Adjuvant Elicited Protective Immunity against Human Respiratory Syncytial Virus in BALB/c Mice.
    Fang Q; Li H; Ren H; Cao L; Hu H; Zhang Y; Xu W
    Jpn J Infect Dis; 2023 May; 76(3):183-190. PubMed ID: 36724936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection.
    Li H; Ren H; Zhang Y; Cao L; Xu W
    Sci Rep; 2021 Sep; 11(1):18641. PubMed ID: 34545126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.
    Palomo C; Mas V; Thom M; Vázquez M; Cano O; Terrón MC; Luque D; Taylor G; Melero JA
    J Virol; 2016 Jun; 90(11):5485-5498. PubMed ID: 27009962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.
    Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Kwon YM; Graham BS; Kang SM
    Virology; 2019 Aug; 534():1-13. PubMed ID: 31163351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
    Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
    PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine.
    Klinguer-Hamour C; Libon C; Plotnicky-Gilquin H; Bussat MC; Revy L; Nguyen T; Bonnefoy JY; Corvaïa N; Beck A
    Vaccine; 2002 Jun; 20(21-22):2743-51. PubMed ID: 12034101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.
    Passmore C; Makidon PE; O'Konek JJ; Zahn JA; Pannu J; Hamouda T; Bitko V; Myc A; Lukacs NW; Fattom A; Baker JR
    Hum Vaccin Immunother; 2014; 10(3):615-22. PubMed ID: 24326268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory Syncytial Virus F Subunit Vaccine With AS02 Adjuvant Elicits Balanced, Robust Humoral and Cellular Immunity in BALB/c Mice.
    Zheng Y; Bian L; Zhao H; Liu Y; Lu J; Liu D; Zhang K; Song Y; Luo Y; Jiang C; Chen Y; Zhang Y; Kong W
    Front Immunol; 2020; 11():526965. PubMed ID: 33013922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.
    Farrag MA; Amer HM; Öhlschläger P; Hamad ME; Almajhdi FN
    Hum Vaccin Immunother; 2017 Jul; 13(7):1586-1597. PubMed ID: 28272978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
    Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
    J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior respiratory syncytial virus infection reduces vaccine-mediated Th2-skewed immunity, but retains enhanced RSV F-specific CD8 T cell responses elicited by a Th1-skewing vaccine formulation.
    Eichinger KM; Kosanovich JL; Perkins TN; Oury TD; Petrovsky N; Marshall CP; Yondola MA; Empey KM
    Front Immunol; 2022; 13():1025341. PubMed ID: 36268035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.
    Zeng R; Qi X; Gong W; Mei X; Wei L; Ma C; Yin X
    Vaccine; 2007 Oct; 25(42):7422-8. PubMed ID: 17850930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.
    Lee Y; Lee YT; Ko EJ; Kim KH; Hwang HS; Park S; Kwon YM; Kang SM
    Hum Vaccin Immunother; 2017 Nov; 13(11):2594-2605. PubMed ID: 28854003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.
    Céspedes PF; Rey-Jurado E; Espinoza JA; Rivera CA; Canedo-Marroquín G; Bueno SM; Kalergis AM
    Vaccine; 2017 Feb; 35(5):757-766. PubMed ID: 28065474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.